Director - Prof. Sunit K. Singh
Prof. Sunit K. Singh
Dr. B.R. Ambedkar Center for Biomedical Research (ACBR) is a unique center, which is engaged to train the young minds in the area of Biomedical education and research under the University of Delhi. ACBR is committed to solve problems and unmet needs related to the human well-being in the today’s era of rapidly evolving world. The thrust areas of research at ACBR apply across a broad spectrum of academic disciplines include Drug Discovery and Drug Development, Medical Biotechnology, Molecular Modeling and DNA Diagnostics, Molecular Oncology, Immunology, Genomics & Proteomics, Medicinal Chemistry, Cancer Genetics, Human Genetics and Neuropharmacology. A major challenge in biology is to comprehend the enormous complexity of biological systems, and to translate this knowledge from bench to bedside in order to add value in the improvement of the health and wellbeing of the people. The insights in understanding the principles governing the biological system will have a fruitful impact in achieving the goals, which are directly or indirectly linked to the health and disease. ACBR has made its place both nationally and internationally based on the quality research and training. ACBR would like to strengthen the existing central facilities, which are the backbone for education, research and training. I believe this effort will be very useful for the students and faculty members.Click More
New website
Recent Activities:
Open Elective Subject:
Provisional list of Open Elective for Application of Statistics for Biology, 2024
Provisional list of Open Elective for Bioethics & Bio-safety, 2024
The registration process for the Ph.D. programs of University of Delhi for the Academic Session 2024-25
Corrigendum for Ph.D. Bulletin of Information 2024-25
Notice for Ph.D. admission 2024-25
12th workshop on Bioinformatics and Drug Design: Artificial Intelligence & Machine Learning Based Methods (BIF-DD-2024) 18th to 20th December, 2024
Schedule for 12th workshop on Bioinformatics and Drug Design: 2024